(Sharecast News) - Scancell reported further positive clinical data for its DNA cancer immunotherapy iSCIB1+, on Tuesday, saying updated phase two results supported its selection for late-stage development in first-line advanced melanoma and reinforce the target patient population.
The AIM-traded company said it would present the data at the ESMO Immuno-Oncology...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE